🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05588284
Enrolling by invitation Not applicable

Preservation of Venous Valvular Function After PMT for Acute DVT

NCT05588284 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase
Not applicable
Started
2022-06-06
Last updated
2026-05-05

Condition(s) studied

Acute Deep Venous Thrombosis of Femoral Vein (Disorder)

Investigational drug(s) / intervention(s)

AngioJet deviceanticoagulation alone

AngioJet device: A device can be used for thrombus aspiration and thrombolysis.

anticoagulation alone: a medicine for anticoagulation therapy

Study summary

To evaluate the venous valvular function after pharmacomechanical thrombectomy (PMT) for acute femoral-popliteal venous thrombosis.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Patients with acute symptomatic proximal DVT involving the femoral, and/or popliteal vein, common femoral vein, iliac veins (with or without other involved ipsilateral veins) were enrolled at seven vascular centers in China. Patients were treated with PCDT via Zelante device (Boston Scientific). Exclusion Criteria: * Participants were excluded if they had symptoms for more than 14 days.

Primary outcome measure(s)

Trial sites (7)

FacilityCityRegionStatus
Chuzhou People's Hospital Chuzhou Anhui
Center hospital of Putu Shanghai Shanghai Municipality
Central Hospital of Songjiang Shanghai Shanghai Municipality
North Branch of Shanghai Ninth People's Hospital Shanghai Shanghai Municipality
Shanghai Ninth People's Hospital Shanghai Shanghai Municipality
Fengchen Hospital Shanghai Shanghai Municipality
Taizhou Municipal hospital Taizhou Zhejiang

More Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05588284 on ClinicalTrials.gov ↗ ← All trials in China